MS/MS

Bruker Introduces Novel 4D-Proteomics™ timsTOF® Capabilities

Retrieved on: 
Monday, September 18, 2023
Research, Technology, Medical Supplies, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, Science, Informatics, LC, BRKR, MALDI, Urine, Serum, TIMS, SP3, Pathology, University of Mainz, Proteomics, Demichev, Multimedia, PG, Biomarker, DDA, Assistant, Associate, Harvard Medical School, Plasma, De novo peptide sequencing, Protein, Acquisition, Kyoto University, Saliva, LC-MS, Ultra, CCS, CSF, MS/MS, Hospital, Fluid mechanics, LC/MS, Boston Children's Hospital, Peptide, Fine chemical, Bruker

View the full release here: https://www.businesswire.com/news/home/20230918138030/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230918138030/en/
    Bruker introduces TIMSquant a scalable, CCS-enabled AI-powered label-free quantification algorithm integrated into Bruker ProteoScape™.
  • We leverage the robustness of our timsTOF instruments and real-time Bruker ProteoScape to build large spectral libraries and analyze 1000s of clinical research samples.
  • Bruker is initiating a limited early-access program for midia-PASEF for immunopeptidomics and post-translational modifications (PTMs) on the ultra-sensitive timsTOF Ultra.
  • To all colleagues in search of top-tier high-throughput data, I endorse the PepSep MAX HT.”
    To ensure optimal run conditions for every sample, Bruker introduces TwinScape™, a digital twin for the timsTOF platform, using Bruker ProteoScape software and the Biognosys iRT kit.

New Release of Genedata Expressionist For Innovative Characterization and Automated Quality Monitoring of Next-Generation Biotherapeutics

Retrieved on: 
Tuesday, October 18, 2022
Time, Molecule, Review, Workflow, Oligonucleotide, CQA, Intelligence, D, Technology, ROI, Automation, Knowledge, Solution, Drug discovery, Industry, Mass spectrometry, CEO, Safety, Tandem mass spectrometry, Data analysis, MS/MS, Fine chemical, Genedata

BASEL, Switzerland, Oct. 18, 2022 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Expressionist® 16.5, the latest version of its platform for streamlining and automating mass spectrometry data workflows, from early discovery to late-stage development. Genedata Expressionist 16.5 takes characterization and quality monitoring of biotherapeutics and oligonucleotides to the next level by enabling leading biopharma companies to fully leverage the potential of mass spectrometry data in their R&D workflows, irrespective of the instrument or technology applied.

Key Points: 
  • Genedata Expressionist 16.5 takes characterization and quality monitoring of biotherapeutics and oligonucleotides to the next level by enabling leading biopharma companies to fully leverage the potential of mass spectrometry data in their R&D workflows, irrespective of the instrument or technology applied.
  • This release further enhances the established characterization workflows built into Genedata Expressionist for the identification of multiple clipping events in biotherapeutics.
  • As the industry leader in end-to-end automation of MS data analysis, Genedata Expressionist now offers automated product quality monitoring of emerging modalitiessuch as therapeutic oligonucleotides.
  • "The inherent complexity of innovative biotherapeutics necessitates comprehensive characterization and robust product quality assessment.

Alturas Analytics Announces Groundbreaking for Expansion Laboratory

Retrieved on: 
Monday, July 25, 2022
CRO, Foot, PK, Growth, Solution, Alturas, California, MS/MS, Fine chemical

MOSCOW, Idaho, July 25, 2022 /PRNewswire-PRWeb/ -- Alturas Analytics, Inc. is pleased to announce the groundbreaking for expansion of their facilities took place July 20th. The new building will add 17,500 square feet to the current footprint and occupy the lots adjacent to its main facility located in the Alturas Technology Park.

Key Points: 
  • Alturas Analytics breaks ground on 17,500 square foot expansion facility.
  • MOSCOW, Idaho, July 25, 2022 /PRNewswire-PRWeb/ -- Alturas Analytics, Inc. is pleased to announce the groundbreaking for expansion of their facilities took place July 20th.
  • Alturas Analytics, Inc. has been privately owned and operated in Moscow, Idaho since September 2000, providing bioanalytical support to pharmaceutical and biotech companies worldwide.
  • Alturas Analytics, Inc. is a GLP-compliant bioanalytical CRO, specializing in MS/MS solutions to support early discovery through late-phase clinical trials.

Tobias Kind, Leader in Computational Metabolomics, Joins Enveda Biosciences

Retrieved on: 
Wednesday, July 20, 2022
Biotechnology, Science, Health, Research, Metabolomics, Chemistry, Time, University, Data science, Paulinum (University of Leipzig), Research, Drug discovery, Fritz Haber Institute of the Max Planck Society, Max Planck Institute of Molecular Plant Physiology, University of California, Davis, Multimedia, UC, List of life sciences, Leadership, Machine learning, Ecotoxicology, Biotechnology, Technology, Research fellow, Mass spectrometry, Max Planck Society, MS/MS, Pharmaceutical industry, Risk management, Fine chemical

Dr. Kind is one of the worlds most respected and highly cited researchers in computational metabolomics and natural products research.

Key Points: 
  • Dr. Kind is one of the worlds most respected and highly cited researchers in computational metabolomics and natural products research.
  • View the full release here: https://www.businesswire.com/news/home/20220720005814/en/
    Enveda Biosciences today announced that Tobias Kind, one of the world's most respected computational metabolomics researchers, is joining the company's industry-leading data science team as Research Fellow.
  • Before joining Enveda, Dr. Kind was a team leader and senior researcher at the University of California, Davis.
  • Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery.

Agilent Announces New Oligonucleotide Analysis Software for Biopharma Research

Retrieved on: 
Monday, June 6, 2022
Technology, Research, Software, Biotechnology, Health, Electronic Design Automation, Pharmaceutical, Data Management, Science, Conference, Research, MS/MS, III, Oligonucleotide, LinkedIn, Software, News, Agilent Technologies, Therapy, Solution, Gene expression, NYSE, Compliance, Quality of life, Twitter, Mass spectrometry, Arrowhead Pharmaceuticals, Fine chemical, Facebook

Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide purity analysis and sequence confirmation.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide purity analysis and sequence confirmation.
  • Agilent MassHunter BioConfirm 12.0 software introduces enhancements to existing capabilities for protein analysis and adds support for oligonucleotide analysis.
  • The addition of oligonucleotide support to MassHunter BioConfirm aligns with Agilents continued focus on the needs of our biopharma customers."
  • Im excited about the new oligonucleotide analysis package Agilent has developed.

Expanded Liquid Chromatography-Mass Spectrometry Platform Provides All-in-One Toxicology Solution

Retrieved on: 
Monday, June 6, 2022
Technology, Research, Software, Biotechnology, Hardware, Health, Pharmaceutical, Other Science, Science, Science, ASMS, Applied Biosystems, Conference, Minneapolis, Research, Patheon, MS/MS, Society, Minneapolis Convention Center, Forensic toxicology, Invitrogen, Software, Institute of Analytical Sciences, Database, American Society for Mass Spectrometry, LC-MS, NPS, Multimedia, PPD, Library, Exploris, MS2, MS, Fisher Scientific, Laboratory, Health, LC, Acquisition, Thermo Fisher Scientific, Fentanyl, Toxicology, Mass spectrometry, LGC, Illegal drug trade, The Explorers (collection), Plasma protein binding, West Pharmaceutical Services explosion, Mindful Scientific Inc., Running, Fine chemical, Typesetting, Medical device

This toxicology solution offers a standardized method with LC retention times that allows users to get up and running fast.

Key Points: 
  • This toxicology solution offers a standardized method with LC retention times that allows users to get up and running fast.
  • This solution comes complete with the software, service and support to sustain laboratory productivity.
  • Overall, the Tox Explorer Collection for Orbitrap Exploris 120 MS provides a powerful solution for forensic toxicology.
  • Thermo Scientific Orbitrap Exploris 120 MS provides ultra-high-resolution MS, HRAM specificity and polarity switching for fast, accurate and reportable results.

Open Access Accurate Mass Extractable and Leachable MS/MS Library Developed by SCIEX and Pall Corporation

Retrieved on: 
Wednesday, April 27, 2022
Biotechnology, Practice Management, FDA, Other Health, Health, General Health, Pharmaceutical, Medical Devices, Research, Fitness & Nutrition, Science, IDS, Filtration, Research, Plastic, Mass spectrometry, Polymer, MS/MS, Biomarker, Mass, Health, Excipient, Solution, Pall Corporation, Algorithm, ID, Safety, Multimedia, Disease, Library, Fine chemical, Pharmaceutical industry, SCIEX

View the full release here: https://www.businesswire.com/news/home/20220427005352/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220427005352/en/
    SCIEX, in collaboration with Pall Corporation, launch an open access extractable and leachable (E&L) MS/MS spectral library consisting of 675 compound entries.
  • This library release includes high-quality, accurate mass spectra for relevant chemical species and moieties, allowing for automated, simultaneous ID and quantification.
  • This open access library is part of our commitment to help scientists accelerate their research and make impactful discoveries, said Jose Castro-Perez, Senior Director of Accurate Mass from SCIEX.
  • Together with SCIEX, Pall Biotechs market-leading advanced extractables and leachables knowledge and experience have contributed to this comprehensive open access library.